FindMyKOL
Clinical trialNCT04383587CompletedInterventional

Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers

NCT04383587 is an interventional trial sponsored by Mayo Clinic. As of 21 Nov 2026, it is completed. It studies COVID-19 and SARS-CoV 2. The registry lists an enrollment of 300 participants at 1 site in 1 country. The registry lists a start date of 6 May 2020 and a primary completion date of 1 Jul 2020.

SponsorMayo Clinic →Enrollment300COVID-19SARS-CoV 2
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04383587
FieldValue
Registry IDNCT04383587
StatusCompleted
Study typeInterventional trial
Lead sponsorMayo Clinic
Enrollment300
Registered sites1
Countries1
ConditionsCOVID-19 and SARS-CoV 2
Start6 May 2020
Primary completion1 Jul 2020
Study completion31 Jul 2020
Last update posted13 Apr 2022

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could inform further decisions about widespread antibody testing in a healthcare worker population.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • Mayo Clinic in Florida

    Jacksonville

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04383587

Each answer restates registry values shown on this page.

What is NCT04383587?

NCT04383587 is an interventional trial sponsored by Mayo Clinic. It studies COVID-19 and SARS-CoV 2.

Who leads NCT04383587?

The registry names Mark Parkulo, MD (principal investigator, Mayo Clinic) as the overall official.

Where does NCT04383587 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When did NCT04383587 end?

The registry lists a primary completion date of 1 Jul 2020 and a study completion date of 31 Jul 2020. The sponsor last updated the record on 13 Apr 2022.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.